|
FERMT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.57329999994626E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.42030000000104E-06 |
| Normal-vs-Stage2 |
3.28699999996296E-06 |
| Normal-vs-Stage3 |
1.28450000003166E-06 |
| Normal-vs-Stage4 |
1.28269999999375E-06 |
| Stage1-vs-Stage2 |
6.124000E-01 |
| Stage1-vs-Stage3 |
3.523800E-01 |
| Stage1-vs-Stage4 |
3.501200E-01 |
| Stage2-vs-Stage3 |
8.555000E-01 |
| Stage2-vs-Stage4 |
7.172200E-01 |
| Stage3-vs-Stage4 |
8.512000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.47380000004027E-06 |
| Normal-vs-AfricanAmerican |
8.765400E-04 |
| Normal-vs-Asian |
1.200980E-04 |
| Caucasian-vs-AfricanAmerican |
2.751800E-01 |
| Caucasian-vs-Asian |
2.686600E-01 |
| AfricanAmerican-vs-Asian |
8.219800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.59549999948439E-07 |
| Normal-vs-Female |
2.68680000004018E-06 |
| Male-vs-Female |
2.212200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.50610000000584E-05 |
| Normal-vs-Age(41-60Yrs) |
9.16750000024003E-07 |
| Normal-vs-Age(61-80Yrs) |
2.20230000014254E-07 |
| Normal-vs-Age(81-100Yrs) |
4.512400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.311900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.004290E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.997000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.275000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.482000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.984000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.796240E-02 |
| Classical-VS-Follicular |
5.441000E-03 |
| Classical-VS-Other |
4.226000E-02 |
| Classical-VS-Normal |
3.77449999999779E-05 |
| Tall-VS-Follicular |
9.226600E-01 |
| Tall-VS-Other |
2.507800E-01 |
| Tall-VS-Normal |
5.78940000051098E-07 |
| Follicular-VS-Other |
2.978600E-01 |
| Follicular-VS-Normal |
3.8386000000834E-07 |
| Other-VS-Normal |
7.319500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.68040000025904E-07 |
| Normal-vs-N1 |
3.54080000000145E-05 |
| N0-vs-N1 |
1.721800E-01 |
|
|
